Vir Biotechnology, INC Form 4 insider transactions

Robert J More, a Director of Vir Biotechnology, Inc., reported multiple transactions in common stock on August 11, 2026.

Director Timothy Coughlin acquired 16,000 shares of restricted stock units and 32,000 stock options in Vir Biotechnology, Inc.

Director Janet Napolitano sold 3,200 shares of Vir Biotechnology, Inc. common stock at a price of $9.45 per share.

Brent Sabatini, SVP and Chief Accounting Officer of Vir Biotechnology, sold 379 shares of common stock on June 1, 2026.

Director Charles Elliott Sigal was granted 8,000 restricted stock units and 16,000 stock options by Vir Biotechnology, Inc.

Director Janet Napolitano acquired 8,000 restricted stock units and 16,000 stock options as part of Vir Biotechnology's equity incentive plan.

Director Robert J. More acquired 8,000 restricted stock units and 16,000 stock options as part of Vir Biotechnology's equity incentive plan.

Director Jeffrey S. Hatfield was granted 8,000 restricted stock units and 16,000 stock options by Vir Biotechnology.

Director Ramy Farid acquired 8,000 restricted stock units and 16,000 stock options as part of Vir Biotechnology's equity incentive plan.

Director Norbert W. Bischofberger acquired 8,000 restricted stock units and 16,000 stock options as part of an equity incentive plan.

Vicki Sato, a Director at Vir Biotechnology, Inc., reported the sale of 22,000 shares of common stock for approximately $220,948 under a pre-arranged 10b5-1 trading plan.

CEO Marianne De Backer transferred 233,532 shares of Vir Biotechnology common stock to a family trust for estate planning.

Marianne De Backer, President and CEO of Vir Biotechnology, Inc., reported a transaction involving the sale of common stock under a pre-arranged Rule 10b5-1 trading plan.

Director Vicki Sato sold 22,000 shares of Vir Biotechnology, Inc. common stock on April 1, 2026, via a 10b5-1 plan.

Vir Biotechnology's SVP, Chief Accounting Officer, Brent Sabatini, sold 7,711 shares of common stock for $9.12 per share under a pre-arranged trading plan.

Vir Biotechnology's EVP & CFO, Jason O'Byrne, transferred 2,500 shares of common stock to a family trust for estate planning purposes.

Vir Biotechnology Director Vicki L. Sato sold over 22,000 shares of common stock on March 2, 2026, pursuant to a pre-arranged trading plan.

Vir Biotechnology Director Vicki L. Sato exercised stock options and subsequently sold a portion of her common stock holdings under a pre-arranged 10b5-1 trading plan.

Vir Biotechnology's SVP, Chief Accounting Officer, Brent Sabatini, sold 1,430 shares of common stock to cover tax withholding from RSU vesting.

Vir Biotechnology's EVP & CFO, Jason O'Byrne, sold 1,634 shares of common stock to cover tax withholding obligations from restricted stock unit vesting.

Vir Biotechnology's EVP and Chief Medical Officer, Mark Eisner, reported sales of common stock totaling 3,505 shares under pre-arranged trading plans.

Vir Biotechnology's EVP, General Counsel, and Corporate Secretary, Vanina de Verneuil, sold shares under pre-arranged trading plans.

Vir Biotechnology CEO Marianne De Backer sold 14,762 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Vir Biotechnology's SVP, Chief Accounting Officer, Brent Sabatini, received new equity awards and sold shares to cover tax obligations.

Vir Biotechnology's EVP & CFO Jason O'Byrne reported the acquisition of 55,000 restricted stock units and 110,000 stock options, alongside a tax-related sale of 2,089 shares.

Vir Biotechnology's EVP and Chief Medical Officer, Mark Eisner, reported the acquisition of restricted stock units and stock options, alongside a mandatory sale of shares for tax obligations.

A Vir Biotechnology executive acquired significant equity and options, while also selling shares to cover tax obligations.

Vir Biotechnology CEO Marianne De Backer reported the acquisition of restricted stock units and stock options, alongside a mandatory sale of shares for tax obligations.

Vir Biotechnology Director Vicki L Sato sold 22,000 shares of common stock for a weighted average price of $7.7123 per share under a pre-arranged trading plan.

Vir Biotechnology Director Vicki L. Sato sold 22,000 shares of common stock for a weighted average price of $5.9265 per share, pursuant to a Rule 10b5-1 trading plan.